Clinical trials: Histological Type of Neoplasm
Plasmacytoma, Plasmacytoma of Bone
A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma
The purpose of this study is to investigate if the combination of CC-486 with lenalidomide and radiation therapy is a safe and effective treatment for plasmacytoma.
- Conditions
- Plasmacytoma, Plasmacytoma of Bone, Multiple Myeloma
- Trial name
- NCT04174196
- Testing
- CC-486, Lenalidomide, Radiation Therapy
- Where
- 7 sites in United States
- Volunteers
- 21 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Renal Cell Carcinoma
Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)
Sorafenib and pazopanib are both effective and promising treatments for advanced Renal Cell Carcinoma (RCC). Both drugs are registered for this indication.
- Trial name
- NCT01613846
- Testing
- Sorafenib+Pazopanib, Pazopanib+Sorafenib
- Where
- 72 sites in Austria, Germany and 1 more
- Volunteers
- 544 people
- Sponsor
- Technical University of Munich
Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders
This clinical trial is studying how well giving fludarabine phosphate and melphalan together with total-body irradiation followed by donor stem cell transplant works in treating patients with hematologic cancer or bone marrow…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT00856388
- Testing
- fludarabine phosphate, melphalan, total-body irradiation
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Roswell Park Cancer Institute
HFrEF - Heart Failure With Reduced Ejection Fraction, Chronic Kidney Disease
Swedish Cardiac And Renal Failure Study-1
Previous studies have shown that patients with heart failure with reduced pumping function and preserved kidney function experience improved symptoms, longer survival, and fewer hospitalizations when treated with medications such…
- Trial name
- SCARF-1 (NCT07029503)
- Testing
- Eplerenone
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Karolinska Institutet
Nasopharyngeal Carcinoma
TOMO Versus IMRT in Nasopharyngeal Carcinoma Patients
Tomotherapy is a new radiation planning and delivery technology which may allow for delivery of higher radiation doses with less damage to normal tissues.
- Trial name
- NCT03588403
- Testing
- TOMO, IMRT
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Zhejiang Cancer Hospital
Acute Myeloid Leukemia
Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AML
Cord blood transplantation (CBT) is an alternative option for patients with pediatric acute leukemia that indicated stem cell transplantation.
- Trial name
- NCT00887042
- Testing
- Fludarabine, Busulfan, Thymoglobulin
- Where
- South Korea
- Volunteers
- 35 people
- Sponsor
- The Korean Society of Pediatric Hematology Oncology
Early-stage, Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL
The current study is a phase II multi-center single arm trial to evaluate the efficacy and safety of adding Anti-PD-1 antibody in an inductive and concurrent way to radiotherapy in early-stage low-risk extranodal NK/T cell…
- Trial name
- NCT05149170
- Testing
- Anti-PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese Academy of Medical Sciences
Acute Myeloid Leukemia
Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001)
The purpose of this study is to assess the safety of OCV-501 in patients with AML who completed the Study 311-10-001 and were judged that there was no relapse by any inspections in the end of the study.
- Trial name
- NCT01475370
- Testing
- OCV-501
- Where
- Japan
- Volunteers
- 18 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Kidney Cancer
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy…
- Trial name
- NCT00027573
- Testing
- filgrastim, therapeutic allogeneic lymphocytes, cyclophosphamide
- Where
- 6 sites in United States
- Volunteers
- 36 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Adult Liver Cancer
Accuracy Assessment for Computer-assisted Surgical Interventions of the Liver
Preoperative image-guided data correlates with the actual intraoperative reality. Computer-assisted preoperative planning combined with intraoperative mapping of even very small lesions allows for improved accuracy during…
- Trial name
- CALS (NCT01474694)
- Testing
- Abdominal surgery
- Where
- Switzerland
- Volunteers
- 14 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Breast Cancer, Melanoma
Immunological Variables Associated to ICI Toxicity in Cancer Patients
This is a monocentric, prospective, pilot study that will enrol 435 subjects with solid tumours that are treated with immune checkpoint inhibitor(s) (ICI) alone or in combination with chemotherapy or targeted therapy.
- Conditions
- Breast Cancer, Melanoma, Non Small Cell Lung Cancer, Non-melanoma Skin Cancer
- Trial name
- NCT05429866
- Testing
- Checkpoint Blockade, Immune
- Where
- Belgium
- Volunteers
- 441 people
- Sponsor
- Jules Bordet Institute
Acute Myeloid Leukemia
Everolimus (RAD001) in Elderly Patients With Acute Myeloid Leukemia
The main goal of this study is to assess the safety and tolerability of RAD001 in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy.
- Trial name
- NCT00636922
- Testing
- RAD001(Everolimus)
- Where
- Australia
- Volunteers
- 40 people
- Sponsor
- Bayside Health
Testicular Cancer, Germ Cell Cancer
Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer
The purpose of this study is to determine whether the drug everolimus is effective in the treatment of patients with relapsed cancer of the testis.
- Trial name
- RADIT (NCT01242631)
- Testing
- Everolimus
- Where
- 8 sites in Germany
- Volunteers
- 25 people
- Sponsor
- Hannover Medical School
Hodgkin's and Non-Hodgkin's Lymphoma
Dual Time Point PET in Lymphoma
This study aims to investigate the value of dual time point PET/CT in lymphoma. Since FDG uptake is linked to glucose metabolism, PET imaging is also used to detect suspected sites for infectious and inflammatory disorders.
- Trial name
- NCT01894945
- Where
- 2 sites in Denmark
- Volunteers
- 30 people
- Sponsor
- Odense University Hospital
Hepatocellular Carcinoma
SNMC (Stronger Neo-Minophagen C ) for Acute Hepatitis Post Transarterial Chemoembolization Therapy
A glycyrrhizin-containing product, Stronger Neo-Minophagen C TM (SNMC; Minophagen Pharmaceutical Co.Ltd.,Tokyo,Japan),is widely used in Japan for suppression of hepatitis activity and for prevention of disease progression in…
- Trial name
- NCT04015245
- Testing
- Stronger Neo-Minophagen C
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Chimei Medical Center
Chronic Myelogenous Leukemia (CML), Acute Myelogenous Leukemia (AML)
Unrelated Umbilical Cord Blood (UBC)Transplantation
Hematopoietic progenitor cell (HPC- primitive cells in the blood, bone marrow and umbilical cord that can restore the bone marrow) transplant can be a curative therapy for the treatment of hematologic malignancies (a disease of…
- Conditions
- Chronic Myelogenous Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome, Multiple Myeloma
- Trial name
- NCT01768845
- Testing
- umbilical cord blood (UCB)
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- West Virginia University
Acute Monocytic Leukemia, Acute Myeloid Leukemia
Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
This phase II trial tests how well venetoclax with cladribine and cytarabine alternating with azacitidine and venetoclax works in treating patients with newly diagnosed monocytic acute myeloid leukemia (AML) and active signaling…
- Trial name
- NCT06504459
- Testing
- Azacitidine, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- OHSU Knight Cancer Institute
High-grade Glioma, Diffuse Intrinsic Pontine Glioma
IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG)
This is a phase I study to assess the safety and feasibility of IL-8 receptor modified patient-derived activated CD70 CAR T cell therapy in newly diagnosed and recurrent CD70+ Pediatric High-Grade Gliomas (pHGG) and Diffuse…
- Trial name
- Peds IMPACT (NCT06946680)
- Testing
- Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Florida
Oral Cavity Squamous Cell Carcinoma
Lattice-Based Radiotherapy and Chemo-Immunotherapy for Oral Cavity Squamous Cell Carcinoma
Single-arm, two-part, phase IB safety study that uses a Bayesian Optimal Interval (BOIN-12) dose-escalation scheme. Part 1 (Dose Finding) - Sentinel start at 9 Gy × 3 followed by fixed 3-patient BOIN cohorts exploring 8 Gy × 3 →…
- Trial name
- NCT07335380
- Testing
- Chemotherapy, Lattice Radiotherapy (LRT)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- NYU Langone Health
Acute Lymphocytic Leukaemia
SAR3419 in Acute Lymphoblastic Leukemia
Primary Objective: Participants achieving an Objective Response Rate Secondary Objectives: Response duration Progression Free Survival Minimal residual disease Safety Pharmacokinetics
- Trial name
- MYRALL (NCT01440179)
- Testing
- SAR3419
- Where
- 11 sites in United States, France
- Volunteers
- 100 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.